NARENDRA KUMAR

Dr. NARENDRA KUMAR

Texas A&M University, College Station, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2000 in Process Biochemistry
Verified
Journal Article
Closed access
NKNARENDRA KUMAR
NARENDRA KUMAR
DDDebabrata Das
Debabrata Das

1 September 2001 in Enzyme and Microbial Technology
Verified
Journal Article
Closed access
NKNARENDRA KUMAR
NARENDRA KUMAR
DDDebabrata Das
Debabrata Das

1 June 2013 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
JMJayshree Mishra
Jayshree Mishra
JDJoseph Drummond
Joseph Drummond
SQSohel H. Quazi
Sohel H. Quazi
SKSatya Sridhar Karanki
Satya Sridhar Karanki
JSJ.J. Shaw
J.J. Shaw
NKNARENDRA KUMAR
NARENDRA KUMAR

1 August 2008 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
VNVishal S. Narang
Vishal S. Narang
CFCharles Fraga
Charles Fraga
NKNARENDRA KUMAR
NARENDRA KUMAR
JSJun Shen
Jun Shen
STStacy Throm
Stacy Throm
CWChristopher M. Waters
Christopher M. Waters
Brain edema is an important factor leading to morbidity and mortality associated with primary brain tumors. Dexamethasone, a synthetic glucocorticoid, is routinely prescribed with antineoplastic agents to alleviate pain associated with chemotherapy and reduce intracranial pressure. We investigated whether dexamethasone treatment increased the expression and activity of multidrug resistance (MDR) transporters at the blood-brain barrier. Treatment of primary rat brain microvascular endothelial cells with submicromolar concentrations of dexamethasone induced significantly higher levels of drug efflux transporters such as breast cancer resistance protein (abcg2), P-glycoprotein (P-gp; abcb1a/abcb1b), and MDR protein 2 (Mrp2; abcc2) as indicted by protein and mRNA levels as well as by functional activity. The effect of dexamethasone on transporter function was significant within 6 h of treatment, was dose dependent, and was reversible. Dexamethasone-induced upregulation of Bcrp and P-gp expression and function was partially abrogated by the glucocorticoid receptor (GR) antagonist RU486. In contrast, RU486 had no effect on the dexamethasone-induced upregulation of Mrp2, suggesting a GR-independent regulation of Mrp2, and a GR-dependent regulation of P-gp and Bcrp. In addition to the dexamethasone-induced upregulation of MDR transporters, we measured a dose-dependent and reversible increase in the expression of the nuclear transcription factor pregnane xenobiotic receptor (PXR). Administering dexamethasone to rats caused increased expression of PXR in brain microvessels within 24 h. These results suggest that adjuvant therapy with corticosteroids such as dexamethasone in the treatment of brain tumors may increase the expression of MDR transporters at the blood-brain barrier through pathways involving GR and PXR.

1 January 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NKNARENDRA KUMAR
NARENDRA KUMAR
PZPeilin Zhao
Peilin Zhao
ATAlok Tomar
Alok Tomar
CGCharles A. Galea
Charles A. Galea
SKSeema Khurana
Seema Khurana
Villin, an epithelial cell actin-binding protein, severs actin in vitro and in vivo. Previous studies report that phosphatidylinositol 4,5-bisphosphate (PIP2) regulates actin severing by villin, presumably by interaction with villin. However, direct association of villin with PIP2 has never been characterized. In this report, we presented mutational analysis to identify the PIP2-binding sites in villin. Villin (human) binds PIP2 with a Kd of 39.5 μm, a stoichiometry of 3.3, and a Hill coefficient of 1. We generated deletion mutants of villin lacking putative PIP2-binding sites and examined the impact of these mutations on PIP2 binding and actin dynamics. Our analysis revealed the presence of three PIP2-binding sites, two in the amino-terminal core and one in the carboxyl-terminal headpiece of human villin. Synthetic peptides analogous with these sites confirmed the binding domains. Circular dichroism and quenching of intrinsic tryptophan fluorescence revealed a significant conformational change in these peptides ensuing in their association with PIP2. By using site-directed mutagenesis (arginine 138 to alanine), we demonstrated the presence of an identical F-actin and PIP2-binding site in the capping and severing domain of villin. In contrast, the mutants lysine 822 and 824 to alanine demonstrated the presence of an overlapping F-actin and PIP2-binding site in the actin cross-linking domain of villin. Consistent with this observation, association of villin with PIP2 inhibited the actin capping and severing functions of villin and enhanced the actin bundling function of villin. Our studies revealed that structural changes induced by association with PIP2 could regulate the actin-modifying functions of villin. This study provided biochemical proof of the functional significance of villin association with PIP2 and identified the molecular mechanisms involved in the regulation of actin dynamics by villin and PIP2.

17 January 2022 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
JMJayshree Mishra
Jayshree Mishra
MSMadyson Stubbs
Madyson Stubbs
LKLongxiang Kuang
Longxiang Kuang
NVNitza Vara
Nitza Vara
PKPriyam Kumar
Priyam Kumar
NKNARENDRA KUMAR
NARENDRA KUMAR
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of gastrointestinal (GI) tract with dysregulated mucosal immune functions and disturbed commensal ecosystem of the intestinal lumen. IBD is categorized into two major subsets: Crohn’s disease (CD) and ulcerative colitis (UC). Though advent of biologics has shifted the treatment with relatively longer remission compared to small molecule pharmaceuticals, patients still suffer from long-term complications. Since gut-microbiome is now accepted as another human organ holding potential for long-lasting human health, probiotics, and its engineering hold great promises to treat several previously untreatable chronic inflammatory conditions including IBD. Several emerging biological engineering tools have unlimited potential to manipulate probiotic bacterial system. These can produce useful therapeutic biologics with a goal to either ameliorate and/or treat previously untreatable chronic inflammatory conditions. As gut-microbiome is diverse and vary in different ethnic, geographic, and cultural human population, it will be important to develop vision for personalized probiotic treatment and develop the technology thereof to make personalized probiotic options a reality. The aim of this review paper is to present an overview of the current knowledge on both pharmacological and nonpharmacological IBD treatment modalities with a special emphasis on probiotic strains that are developed through the probiotic engineering. These engineered probiotics contain the most anti-inflammatory cytokines found within the human immune response and are currently being used to treat the intestinal inflammation in IBD for the IBD treatment.